TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.620
-0.100 (-5.81%)
At close: Nov 5, 2026, 4:00 PM EST
1.641
+0.021 (1.28%)
After-hours: Nov 5, 2026, 6:30 PM EST
TuHURA Biosciences Employees
TuHURA Biosciences had 22 employees as of December 31, 2025. The number of employees increased by 3 or 15.79% compared to the previous year. That makes TuHURA Biosciences the 38,087th largest employer in the world and 5,455th in the United States.
Employees
22
Change (1Y)
3
Growth (1Y)
15.79%
Revenue / Employee
n/a
Profits / Employee
-$1,392,365
Market Cap
103.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 22 | 3 | 15.79% |
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| Nkarta | 106 |
| PolyPid | 75 |
| Armata Pharmaceuticals | 61 |
| Anavex Life Sciences | 34 |
| Outlook Therapeutics | 17 |
HURA News
- 1 day ago - TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition - PRNewsWire
- 10 days ago - TuHURA Biosciences Transcript: Study update - Transcripts
- 10 days ago - TuHURA Biosciences Press release: Study update - Filings
- 10 days ago - TuHURA Biosciences reports initial data from study of IFx-2.0 - TheFly
- 10 days ago - TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma - PRNewsWire
- 23 days ago - TuHURA Biosciences granted U.S. patent broadening coverage for VISTA Inhibitor - TheFly
- 23 days ago - TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 - PRNewsWire
- 4 weeks ago - TuHURA Biosciences receives U.S. patent for DOR ADC technology - TheFly